Invention Grant
- Patent Title: BCR-ABL1 splice variants and uses thereof
-
Application No.: US15429640Application Date: 2017-02-10
-
Publication No.: US09957574B2Publication Date: 2018-05-01
- Inventor: Wanlong Ma
- Applicant: Quest Diagnostics Investments Incorporated
- Applicant Address: US DE Wilmington
- Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
- Current Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
- Current Assignee Address: US DE Wilmington
- Agency: Foley & Lardner LLP
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; G01N33/574
Abstract:
The present invention is based on BCR-ABL1 splice variants which result from insertion and/or truncation of the bcr-abl1 transcript and the finding that these variants provide resistance to kinase domain inhibitors such as imatinib, nilotinib and dasatinib.
Public/Granted literature
- US20170306410A1 BCR-ABL1 SPLICE VARIANTS AND USES THEREOF Public/Granted day:2017-10-26
Information query
